Percutaneous Closure of Postinfarction Ventricular Septal Defect, an early alternative to surgery.

Original title: Percutaneous Closure of Postinfarction Ventricular Septal Defect: In-Hospital Outcomes and Long-Term Follow-Up of UK Experience. Reference: Circulation. 2014 Jun 10;129(23):2395-402.

As a mechanical post AMI complication, interventricular communication carries a grim prognosis. Surgery has achieved reasonable outcomes but only for those patients who survive the acute phase of healing. Percutaneous closure is a viable early alternative. 

Between 1997 and 2012 percutaneous closure of postinfarction ventricular septal defect was attempted in 53 patients at 11 UK centers. 66% of MI were anterior and 34% inferior. 

Time from MI to closure procedure was 13 days (5-54 range) and devices were successfully implanted in 89% of the population.

Immediate complications in this high risk population included periprocedural death in 3.8% and emergency cardiac surgery in 7.5% of the population.

Right to left shunt was partially occluded in most of patients (62%), completely occluded in 23% and failed despite device implantation in 15%.

58% of treated patients survived to discharge and were followed up to 395 days. During this period. four additional patients died (7.5%).

Factors more strongly associated to postinfarction mortality included age (HR 1.04; p=0.039), female sex (HR=2.33; p=0.043), NYHA functional class IV (HR=4.42; p=0.002), cardiogenic shock (HR=3.75; p=0.003), need for inotropes (HR=4.18; p=0.005) and the absence of revascularization for presenting MI (HR=3.28; p=0.009).

Prior surgical closure and immediate post implantation shunt reduction were associated with better survival.

Conclusion

Percutaneous closure is a reasonable alternative to treat post infarction percutaneous ventricular septal defect. Although mortality was high, patients who survived to discharge had a good long term prognosis. 

Editorial Comment

This option should be considered especially for those patients that develop cardiogenic shock as a symptom of ventricular septal defect, since surgery at the acute phase is difficult due to the friable nature of septal tissue and waiting, in this context, is hardly a viable option.

SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....